Welcome to MinnesotaLifeScience.com

This network addresses the growing informational and service needs of companies, patients, educators and others in their respective states while providing clients the opportunity to cost effectively advertise their job openings, events, facility availability and other services at the state level, regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting services.

Learn About Minnesota's BioHistory

Through Minnesota BioHistory, you can learn about the scientists, institutions, political leaders, and significant events that have shaped and are still shaping the biotechnology, medical device and life science industries in the state of Minnesota.

Local News...

Free News Release Posting & Archiving Service


• Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye  Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
  Bayer  May 08, 2008  
  
  
• AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder  AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
  AstraZeneca  May 08, 2008  
  
  
• Invitrogen and WARF sign license agreement for human embryonic stem cells  Invitrogen and the Wisconsin Alumni Research Foundation, the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, announced that they have signed a license for human embryonic stem cell patents for the development of research tools.
  Invitrogen Corporation  May 08, 2008  
  
  
• FDA approves Strattera(R) for maintenance of ADHD in children and adolescents  Eli Lilly and Company announced that the United States Food and Drug Administration has approved Strattera(R) (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder in children and adolescents.
  Eli Lilly and Company  May 08, 2008  
  
  
• Boston Scientific announces dismissal of Johnson & Johnson patent lawsuit in Canada  Boston Scientific announced that the Canadian Federal Court has issued judgment in a lawsuit in which Johnson & Johnson had accused the Company's NIR(R) stent of infringing two Johnson & Johnson Palmaz patents.
  Boston Scientific Corporation  May 08, 2008  
  
  

More... | Submit News Release | National News

New Job Postings...

Free Job Posting Trial Offer

• Associate Medical Director, Device Safety Allen Thomas Associates, Inc. (NJ)
• Preclinical Study Coordinator I, II, III SNBL USA, Ltd. (WA)
• Quality Assurance Analytical Auditor SNBL USA, Ltd. (WA)
• Senior Scientist/Senior Study Director, General Tox SNBL USA, Ltd. (WA)
• Medical Director Omeros Corporation (WA)

More... | Job Advertising... | About Job Postings...

Upcoming Events...

Free Event Posting Service

• 05/12/2008: World Pharmaceutical Congress
• 05/12/2008: Advertising, Promotion and Labeling Conference
• 05/12/2008: TechMatch
• 05/12/2008: Generic, Supergenerics & Patent Strategies
• 05/13/2008: 7th Annual Medtech Investing Conference

More... | Submit Event | Event Advertising...